Mannose-Fused Antigen Compositions for Protein Drug Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein-based drugs often elicit an immune response in patients, leading to anti-drug antibodies that can revert therapy efficacy or render it inefficient, highlighting the need for technologies to induce antigen-specific immunological tolerance.
Innovation Solution
Compositions comprising mannose-fused antigens that target mannose receptors, including mannose monomers or derivatives, are used to deliver antigens to antigen-presenting cells, inducing tolerance by deleting antigen-specific CD4 and CD8 T cells, elevating regulatory T cell responses, and reducing plasma cells and memory B cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein-based drugs are administered to patients, then therapeutic effects are achieved, but immune response and anti-drug antibodies are induced
Solution Approach 1:
The patent uses a tolerogenic composition comprising a modified antigen (with reduced immunogenicity) as an intermediary to induce immune tolerance. This modified antigen acts as a mediator that redirects the immune system's response from attacking the therapeutic protein to accepting it as self, thereby resolving the contradiction between maintaining therapeutic efficacy and preventing immune response
Solution Approach 2:
The patent administers a tolerogenic composition before or during therapy to pre-condition the immune system. This preliminary action of inducing tolerance beforehand prevents the development of anti-drug antibodies that would otherwise occur during subsequent administration of the therapeutic protein, thus maintaining therapeutic efficacy without triggering harmful immune responses
2Object-affected harmful factors
If antigen-specific immunological tolerance is induced, then unwanted immune responses are reduced, but new technologies and methods are required
Solution Approach 1:
The patent modifies the antigen's parameters (chemical structure, immunogenicity levels) to create a tolerogenic form that induces immune tolerance. By changing the antigen's properties rather than developing entirely new complex technologies, the patent achieves reduction of unwanted immune responses with a relatively straightforward approach based on antigen modification and controlled administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively induce tolerance to protein-based therapeutics, reducing unwanted immune responses and enhancing therapeutic efficacy by targeting mannose receptors on antigen-presenting cells.
Implementation Method 1
compositions comprising mannose-fused antigens that target mannose receptors... compositions including a mannose or mannose-derived moiety induce tolerance... exhibit affinity for and specifically bind to mannose-binding receptors
Data Source
AI summary
The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.